Behcet's disease uveitis: is there a need for new emerging drugs?

Tugal-Tutkun I., Ozdal P. C.

EXPERT OPINION ON EMERGING DRUGS, vol.25, no.4, pp.531-547, 2020 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 25 Issue: 4
  • Publication Date: 2020
  • Doi Number: 10.1080/14728214.2020.1847271
  • Journal Name: EXPERT OPINION ON EMERGING DRUGS
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Biotechnology Research Abstracts, EMBASE, MEDLINE
  • Page Numbers: pp.531-547
  • Keywords: Behçet’s disease, biological, disease-modifying anti-rheumatic drug, interferon, interleukin-1 inhibitor, interleukin-6 inhibitor, retinal vasculitis, small-molecule inhibitor, tumor necrosis factor inhibitor, uveitis
  • Istanbul University Affiliated: Yes

Abstract

Introduction: Behcet's disease uveitis (BDU) is a potentially blinding disorder. Systemic treatment with disease-modifying anti-rheumatic drugs (DMARDs) is mandatory in patients with intraocular inflammation involving the posterior segment of the eye.